StockData
Oculis Holding AG logo

Oculis Holding AG (OCS) stock

OCSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as OCSAW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 4, 2026Score 1/30
$7.39−0.12 (-1.60%)

Close on Nov 18, 2026Market cap $444.06MP/E –Yield –

Oculis operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -CHF 81.67M. The highest annual figure on record is -CHF 12.34M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-CHF 81.67M–
FY2024Dec 31, 2024-CHF 73.20M–
FY2023Dec 31, 2023-CHF 80.71M–
FY2022Dec 31, 2022-CHF 32.38M–
FY2021Dec 31, 2021-CHF 13.23M–
FY2020Dec 31, 2020-CHF 12.34M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-CHF 23.57M–
Q2 FY2025Jun 30, 2025-CHF 20.77M–
Q2 FY2024Jun 30, 2024-CHF 22.49M–
Q2 FY2023Jun 30, 2023-CHF 10.75M–

More Oculis figures

See a number that looks wrong?